CTOs on the Move


 
Freyr is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.freyrinc.com
  • 103 Carnegie Ctr Ste 300
    Princeton, NJ USA 08540
  • Phone: 908.345.5984

Executives

Name Title Contact Details

Similar Companies

Harbor Biosciences

Harbor Biosciences, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioEnterprise Corporation

BioEnterprise Corporation is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VAYA Pharma

At VAYA Pharma, we are committed to improving quality of life and delivering products that exemplify our key values. VAYA Pharma`s history of clinical research is based on understanding the potential of the human body in order to reform medicine. Through this research, we have discovered a strong correlation between certain disorders and lipid imbalances in affected individuals. Because of this, VAYA Pharma focuses on developing innovations for the clinical dietary management of disorders that are specifically associated with lipid imbalances. Our products deliver a nutritional based solution that are familiar to the human body and clinically proven to be safe and effective with virtually no side effects. Using lipid-based ingredients, our innovative products address nutritional needs of people with health conditions that cannot be met through modification of diet alone.

Gilson

Gilson is a Middleton, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sengenics

Sengenics is a functional proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ was invented and patented by Professor Jonathan Blackburn whilst he was a member of the faculty at the University of Cambridge. Jonathan is the CSO of Sengenics. The key application of KREX™ is the discovery of autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ can also be used to identify autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions years before conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.